Jump to content

Recommended Posts

Posted

http://www.upi.com/HealthBusiness/view. ... 2501-1169r

MALVERN, Pa., May 17 (UPI) -- Neotropix said Wednesday the Food and Drug Administration approved a phase 1 trial of Seneca Valley Virus, a potential cancer therapy.

In the phase 1 trial, Seneca Valley Virus, or SVV-001, will be administered to patients with advanced neuroendocrine cancers, including small cell lung cancer. SVV-001 is a naturally occurring virus with the ability to kill cancer cells.

"Our first product may provide a breakthrough therapy for patients with some of the most serious types of cancer known, such as small cell lung cancer, for which there are few promising therapies under development," said Paul Hallenbeck, Neotropix's founder, president and chief scientific officer.

"Seneca Valley Virus has the potential to be safer and more effective than treatments currently available or even on the horizon, and may help treat some of the most commonly diagnosed cancers among American men and women," Hallenbeck added.

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.